Mizuho Maintains Neutral on Apellis Pharmaceuticals, Raises Price Target to $41

Mizuho analyst Graig Suvannavejh has maintained a Neutral rating on Apellis Pharmaceuticals (NASDAQ: APLS) while raising the price target from $20 to $41. This adjustment reflects a positive outlook on the company's performance.